Apogee Therapeutics, Inc. (APGE)
After hours:
| Previous Close | 53.30 |
| Open | 52.89 |
| Bid | 53.65 x 200 |
| Ask | 53.84 x 100 |
| Day's Range | 52.89 - 54.20 |
| 52 Week Range | 14.19 - 72.29 |
| Volume | |
| Avg. Volume | 720,993 |
| Market Cap | 3.03B |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 84.83 |
GlobeNewswireApogee Announces Dosing of First Patient in Phase 2 Atopic Dermatitis Trial of APG777, a Novel Subcutaneous Half-life Extended Anti-IL-13 Antibody for the Treatment of Atopic Dermatitis and Other Inflammatory Diseases
Interim clinical data from APG777 Phase 1 healthy volunteers study exceeded all trial objectives and achieved a half-life of approximately 75 days with a potentially best-in-class profile 16-week proof-of-concept data from Part A of the Phase 2 trial expected in 2H 2025 Pipeline-in-a-product potential with a Phase 2 in asthma expected to initiate in 2025 and plans for additional indication expansion SAN FRANCISCO and WALTHAM, Mass., May 15, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nas
- GlobeNewswire
Apogee Therapeutics Highlights Pipeline Progress and Reports First Quarter 2024 Financial Results
Initiated a Phase 2 clinical trial of APG777, a subcutaneous half-life extended monoclonal antibody targeting IL-13, in patients with moderate-to-severe atopic dermatitis, with 16-week proof-of-concept data from Part A of the trial expected in 2H 2025 First participant dosed in Phase 1 healthy volunteer clinical trial of APG808, a subcutaneous half-life extended monoclonal antibody targeting IL-4Rα, for the treatment of chronic obstructive pulmonary disease and other inflammatory diseases with i
- GlobeNewswire
Apogee Therapeutics to Participate at the 2024 Bank of America Healthcare Conference
SAN FRANCISCO and WALTHAM, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing differentiated biologics for the treatment of atopic dermatitis, COPD, asthma and other inflammatory and immunology indications, today announced that Michael Henderson, M.D., Chief Executive Officer and Jane Pritchett Henderson, Chief Financial Officer, will participate in a fireside chat at the 2024 Bank of America Healthcare Conference on
